Search

Background and objectives: There is a scarcity of data stemming from largescale epidemiological longitudinal studies focusing on potentially preventable and controllable risk factors for Alzheimer's disease (AD) and AD-related dementia (ADRD). This study aimed to examine the effect of multiple metabolic factors and cardiovascular disorders on the risk of cognitive decline and AD/ADRD. Methods: We analyzed a cohort of 6,440 participants aged 45-84 years at baseline. Multiple metabolic and cardiovascular disorder factors included the five components of the metabolic syndrome [waist circumference, high blood pressure (HBP), elevated glucose and triglyceride (TG) concentrations, and reduced high-density lipoprotein cholesterol (HDL-C) concentrations], C-reactive protein (CRP), fibrinogen, interleukin-6 (IL-6), factor VIII, D-dimer, and homocysteine concentrations, carotid intimal-medial thickness (CIMT), and urine albumin-to-creatinine ratio (ACR). Cognitive decline was defined using the Cognitive Abilities Screening Instrument (CASI) score, and AD/ADRD cases were classified using clinical diagnoses. Results: Over an average follow-up period of 13 years, HBP and elevated glucose, CRP, homocysteine, IL-6, and ACR concentrations were significantly associated with the risk of mortality in the individuals with incident AD/ADRD or cognitive decline. Elevated D-dimer and homocysteine concentrations, as well as elevated ACR were significantly associated with incident AD/ADRD. Elevated homocysteine and ACR were significantly associated with cognitive decline. A dose-response association was observed, indicating that an increased number of exposures to multiple risk factors corresponded to a higher risk of mortality in individuals with cognitive decline or with AD/ADRD. Conclusion: Findings from our study reaffirm the significance of preventable and controllable factors, including HBP, hyperglycemia, elevated CRP, D-dimer, and homocysteine concentrations, as well as, ACR, as potential risk factors for cognitive decline and AD/ADRD. [ABSTRACT FROM AUTHOR]

Background: Heart transplantation (HT) is the only option for most patients with end‐stage heart failure and hypertrophic cardiomyopathy (HCM) who fail medical therapy. Data on the long‐term outcomes post‐transplant in HCM individuals remain scarce. Methods: We analyzed data of 319 adult patients who underwent HT between 1984 and 2019. Patients were followed for cardiac allograft rejection, cardiac allograft vasculopathy (CAV), death, or re‐transplantation. Results: Outcomes of 24 patients with HCM, 160 with ischemic, and 135 with dilated cardiomyopathy were compared. During a mean follow‐up of 11.6 ± 7.2 (max 27.8), 16.7 ± 8.2 (max 32.7), and 16.1 ± 9.7 (max 34.6) years after HT in hypertrophic, ischemic, and dilated cardiomyopathy groups, respectively: 10‐year survival rate was 67%, 62%, 69%, respectively (p =.04). Post‐transplantation, HCM individuals more often than the other two studied groups required prolonged inotropic support (37%, 12%, 17%, respectively, p =.02), temporary mechanical circulatory support (45%, 13%, 14%, respectively, p <.01), and renal replacement therapy immediately post‐HT (55%, 19%, 24%, respectively, p <.01). No significant inter‐group differences were noted in the 10‐year freedom from acute allograft rejection (38%, 46%, 43%, respectively, p =.38) or 10‐year freedom from CAV (88%, 78%, 81%, respectively, p =.57). Conclusions: The long‐term post‐transplant prognosis of adult patients with hypertrophic cardiomyopathy is favorable despite more challenging immediate post‐HT course. [ABSTRACT FROM AUTHOR]